After a personalized dose of radioactive iodine for a toxic thyroid nodule, just over half of patients had normal thyroid function at three months, while nearly half became hypothyroid; by six months, everyone had normal function with hormone replacement.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The pooled rate of euthyroidism and hypothyroidism at 3 and 6 months after dosimetry-based RAI in toxic adenoma across multiple studies.
A systematic review and meta-analysis of all prospective studies reporting thyroid function outcomes at 3 and 6 months after dosimetry-based RAI (targeting 300 Gy) in adults with solitary toxic adenoma, stratified by nodule size and baseline uptake.
Whether dosimetry-based RAI leads to higher euthyroidism rates at 3 months than fixed-dose RAI in toxic adenoma.
A double-blind RCT of 120 adults with toxic adenoma randomized to dosimetry-based RAI (300 Gy target) or fixed-dose RAI (740 MBq), with primary outcome: euthyroid status at 3 months defined by TSH 0.4–4.0 mIU/L and normal fT4.
The natural progression of thyroid function after dosimetry-based RAI in toxic adenoma over time.
A prospective cohort of 200 patients with toxic adenoma treated with dosimetry-based RAI (300 Gy target), followed with monthly thyroid function tests for 6 months, then quarterly for 2 years, to document time to euthyroidism or hypothyroidism.
Whether baseline nodule size or iodine uptake predicts early euthyroidism after dosimetry-based RAI.
A case-control study comparing 40 patients who achieved euthyroidism at 3 months with 80 who developed hypothyroidism after dosimetry-based RAI, analyzing pre-treatment nodule volume, uptake percentage, and TSH receptor antibody levels.
The current prevalence of euthyroidism or hypothyroidism in patients treated with dosimetry-based RAI for toxic adenoma at least 6 months prior.
A cross-sectional survey of 150 patients treated with dosimetry-based RAI for toxic adenoma at least 6 months ago, measuring current TSH, fT4, and levothyroxine use.